Literature DB >> 341538

Antiviral therapy.

H Stalder.   

Abstract

The current status of antiviral therapy is reviewed, including discussion of older approaches together with more recently developed chemotherapy. Following the introduction dealing with pathophysiological aspects of virus disease, the different approaches to antiviral therapy are presented. The reasons for the slow progress in antiviral therapy are discussed. These include: 1. the necessity of intracellular penetration of drugs acting on viral replication; 2. the severe toxicity of most antiviral drugs; 3. the narrow antiviral spectrum of most of these agents; 4. the difficulty of making a rapid etiological diagnosis in view of the necessity of starting (specific?) treatment early in the course of the disease; 5. the difficult evaluation of beneficial as compared with deleterious effects of antiviral therapy. After a detailed review of clinically tested substances, including immunoglobulins, synthetic antiviral drugs (amantadine, nucleoside analogs, thiosemicarbazones and photodynamic dyes) and interferon, a guide concerning indications and application of specific antiviral therapy is presented. Although at present there are few indications, clinicians should be aware of the (present and future) possibilities of antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 341538      PMCID: PMC2595556     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  188 in total

1.  Inhibition by interferon of delayed-type hypersensitivity in the mouse.

Authors:  E De Maeyer; J De Maeyer-Guignard; M Vandeputte
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

Review 2.  Interferon research in the Red Queen's Kingdom.

Authors:  R M Friedman
Journal:  Arch Pathol       Date:  1974-08

3.  Immunosuppressive effects of an interferon preparation in vivo.

Authors:  M S Hirsch; D A Ellis; P H Black; A P Monaco; M L Wood
Journal:  Transplantation       Date:  1974-02       Impact factor: 4.939

Review 4.  Corticosteroids and infectious diseases.

Authors:  D C Dale; R G Petersdorf
Journal:  Med Clin North Am       Date:  1973-09       Impact factor: 5.456

Review 5.  Mechanisms of virus pathogenicity.

Authors:  H Smith
Journal:  Bacteriol Rev       Date:  1972-09

Review 6.  Passive immunization against varicella-zoster infections and other modes of therapy.

Authors:  P A Brunell; A A Gershon
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

Review 7.  Antiviral chemotherapy: the first decade.

Authors:  D J Bauer
Journal:  Br Med J       Date:  1973-08-04

Review 8.  The structure of nucleosides in relation to their biological and and biochemical activity: a summary.

Authors:  A Bloch
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

9.  Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis.

Authors:  R G Knodell; M E Conrad; A L Ginsberg; C J Bell
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

10.  Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.

Authors:  S Barandun; V Castel; M F Makula; A Morell; R Plan; F Skvaril
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

View more
  4 in total

Review 1.  Antiviral agents: action and clinical use.

Authors:  T W Chang; D R Snydman
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

2.  Effects of nucleoside analogs on Epstein-Barr virus-induced transformation of human umbilical cord leukocytes and Epstein-Barr virus expression in transformed cells.

Authors:  E E Henderson; W K Long; R Ribecky
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

3.  Antiviral therapy: a perspective.

Authors:  Amir Hashem Shahidi Bonjar
Journal:  Drug Des Devel Ther       Date:  2016-02-02       Impact factor: 4.162

Review 4.  Antivirals against animal viruses.

Authors:  T G Villa; L Feijoo-Siota; J L R Rama; J M Ageitos
Journal:  Biochem Pharmacol       Date:  2016-09-30       Impact factor: 5.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.